Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland

Rhea-AI Summary

Virax Biolabs (NASDAQ: VRAX) has signed a non-exclusive distribution agreement with French company Tebubio to distribute its ImmuneSelect Research Use portfolio across the European Union, Norway, and Switzerland. The partnership aims to increase accessibility of ImmuneSelect for life science institutions throughout Europe.

Tebubio's established distribution networks and relationships across Europe will facilitate broader access to ImmuneSelect for research purposes. The collaboration represents a strategic expansion of Virax's immune profiling technology in the European market.

Positive

• Expansion of distribution network into European Union, Norway, and Switzerland
• Partnership with established distributor Tebubio enhances market access
• Strategic entry into important European life science research market

Negative

• Non-exclusive distribution agreement limits market control
• Research Use Only portfolio restricts commercial potential

Insights

Market Research Analyst

While this distribution agreement expands Virax's market reach into Europe, several key aspects limit its immediate impact. The agreement is non-exclusive, meaning Tebubio isn't the sole distributor, potentially diluting the partnership's value. The ImmuneSelect product is for research use only, restricting its market to academic and research institutions rather than the broader clinical diagnostic market.

For a micro-cap company like Virax with a market cap of just $7.8 million, distribution partnerships are important for growth, but this particular agreement lacks specific financial terms or revenue projections. The European life sciences research market represents a significant opportunity, but without clear commercial metrics or minimum purchase commitments, the actual revenue impact remains uncertain. The partnership may help build brand awareness and market presence, but its material impact on Virax's financial performance appears in the near term.

LONDON, Dec. 10, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a non-exclusive distribution agreement with French company Tebubio to expand the distribution of its ImmuneSelect Research Use portfolio into countries in the European Union, as well as in Norway and Switzerland.

"We are honored to announce this agreement with Tebubio, who will prove to be instrumental in increasing the accessibility of ImmuneSelect for life science institutions across a crucial market such as Europe," said James Foster, CEO of Virax Biolabs. "This agreement further strengthens our ongoing efforts to advance immune profiling technology and supports a growing need for comprehensive insights into immune health status through ImmuneSelect."

"This collaboration with Virax holds a great significance for our company as it demonstrates our commitment to innovative diagnostic tools such as ImmuneSelect," said Romain Cordonnier-Goulay, CSO of Tebubio. "Our strong distribution networks and relations across Europe will help ImmuneSelect become more accessible to customers to help with their research needs."  

About ImmuneSelect

ImmuneSelect is the Company's portfolio of research products dedicated to investigating adaptive immunity. Products within the ImmuneSelect brand are for research and investigational use only and are not intended to be used as a diagnostics tool. The ImmuneSelect portfolio includes peptide pools covering epitopes from pathogens, optimized for the stimulation of T cells. The initial offerings include pools for SARS-CoV-2, SARS-CoV-2 MHC-1 ("CD8"), Lyme Disease, Cytomegalovirus ("CMV"), Respiratory Syncytial Virus ("RSV") and Epstein-Barr Virus ("EBV"), which continue to be regularly expanded. ImmuneSelect's Recombinant Antibodies target cytokines and biomarkers, and they are available in different versions unconjugated to be tested on a range of applications including Flow Cytometry, ELISA and ELISpot/Fluorospot. ImmuneSelect is affordable, easy to use, and is compatible with most standard laboratory equipment. 

About Virax Biolabs Group Limited

Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.

For more information, please visit www.viraxbiolabs.com.

About Tebubio

We facilitate Life Sciences Research every day, contributing to advance Science for a brighter future. Through our Tebubio local offices located across Europe, we support Life Sciences and Biotechnology Researchers with a unique, holistic range of solutions to advance their projects faster. With Tebubio, concentrate your efforts and accelerate what's most important to you: Your Research.

For more information, please visit www.tebubio.com

Investor Relations Contact:
Russo Partners, LLC 
Nic Johnson
12 West 27th Street 
4th Floor 
New York, NY 10001 
M: 303-482-6405 
nic.johnson@russopartnersllc.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-announces-agreement-with-tebubio-to-expand-distribution-of-immuneselect-across-the-european-union-norway-and-switzerland-302327093.html

SOURCE Virax Biolabs

FAQ

What is the new distribution agreement announced by Virax Biolabs (VRAX) in December 2024?

Virax Biolabs announced a non-exclusive distribution agreement with French company Tebubio to distribute ImmuneSelect Research Use portfolio across the European Union, Norway, and Switzerland.

Which territories are covered in Virax Biolabs (VRAX) distribution agreement with Tebubio?

The distribution agreement covers countries in the European Union, as well as Norway and Switzerland.

What product will Tebubio distribute for Virax Biolabs (VRAX)?

Tebubio will distribute Virax Biolabs' ImmuneSelect Research Use portfolio.